Galleri by GRAIL is a multi-cancer early detection blood test designed to screen for many of the deadliest cancers, including those that currently have no recommended screening methods. The test can identify cancerous DNA fragments, which act like a "fingerprint" of cancer, often before symptoms appear or traditional diagnostic methods can detect it.
As cancers grow, they shed DNA into the bloodstream. The Galleri test detects these DNA fragments, providing an early indication of cancer, known as a "Cancer Signal." In individuals aged 50-79, approximately 1% are expected to receive a positive result, which includes a prediction of the tissue or organ of origin, called the Cancer Signal Origin (CSO). Among those who test positive, around 40% are expected to have a confirmed cancer diagnosis after further diagnostic evaluation.
In clinical studies, the Galleri test accurately identified the correct CSO 88% of the time for participants with a confirmed cancer diagnosis. This prediction helps doctors pinpoint the likely location of the cancer and guides further diagnostic steps.
The Galleri test has been rigorously evaluated in clinical studies with over 20,000 participants and is backed by certifications from the International Organization for Standardization (ISO 15189), Clinical Laboratory Improvement Amendments (CLIA), and accreditation by the College of American Pathologists (CAP).
When tested, you will receive one of two possible results within about two weeks:
No Cancer Signal Detected
Cancer Signal Detected
For nearly 99% of people, no cancer signal will be detected. If a signal is found, the test also predicts the tissue or organ associated with the cancer, providing vital information to guide the next steps in your care.
References
-
Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI: https://doi.org/10.1016/j.annonc.2021.05.806
-
Schrag D, Beer TM, McDonnell CH, et al. Evaluation of Anxiety, Distress and Satisfaction With a Multi-Cancer Early Detection Test. Ann Oncol. 2022;33(suppl 7):S963. DOI: https://doi.org/10.1016/j.annonc.2022.07.1034.
-
Thierry A, El Messaoudi S, Gahan P, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35:347–76. DOI: https://doi.org/10.1007/s10555-016-9629-x.
-
Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. DOI: https://doi.org/10.1016/j.annonc.2020.02.011.
-
Ofman J, Hall M, Aravani A. GRAIL and the quest for earlier multi-cancer detection. Nature Portfolio. March 25 2020.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.